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TWO CASES OF RENAL CELL CARCINOMA WITH 
ASCITES AFTER INTERLEUKIN-2 THERAPY 
Go KOBORI， Masanobu MAEGAWA， Hiroshi USHIDA， Shinya MAEKAWA， 
Koji INouE， Yoshiyuki KANEKO， Kouhei OHMORI and Kazuo NISHIMURA 
From the Department 01 Urology， Osaka Red Cross Hoφital 
One of the most common and problematic side effects of interleukin-2 therapy (IL-2) is vascular 
leak syndrome (VLS). VLS is characterized by an increase in vascular permeability accompanied by 
extravasation of fluids and proteins from the capillary vessels into the tissues resulting in interstitial 
edema， weight gain， pleural effusion， ascites in severe form， multiple organ failure. We， herein， report 
two cases of VLS， which occurred following IL-2 therapy against metastatic renal cel carcinoma. 
One of them died of multiple organ failure one month after the cessation of IL-2 therapy. 











行.病理診断は renalcel carcinoma， clear cel 




分切除術施行した. 9月より IFN・αに変えて IL-2
(70万]RU/日)を 8週間投与したが，投与終了後 l
カ月日の12月より腹水膨満感，全身倦怠感， 3.5 kg 
の体重増加が出現し， CTにて多量の胸水，腹水の貯
留を認めた (Fig.J). 
血液生化学検査(腹水貯留時): TP 5.5 g/dl， ALB 
2.8 g/dl， GOT 19 IU/l， GPT 15 IU/l， CRE 0.8 
*現:静岡県立総合病院泌尿器科
(Acta Urol. Jpn. 48: 455-457， 2002) 
Fig. 1. Computerized tomography (CT) 
showed a large amount of ascites after 
3 months of IL-2 therapy. 
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Fig. 2. Computerized tomography (CT) 
showed a large amount of ascites and 
tumor thrombus (arrow) after 8 days 
of IL-2 therapy. 








血液生化学検査(腹水貯留時): TP 6.3 g/dl， ALB 
2.7 g/dl， GOT 68 IU/l， GPT 38 IU/l， CRE 2.4 















































もな doselimiting factorになっている4) 1995年，
Fyfeらは， 255人の腎細胞癌患者に対し， IL-2大量
療法 (60-72万 IU/kg/8hr)を施行したところ， 1 
例 (4%)が IL・2の副作用が原因で死亡したと報告









Fig. 3. The mechanism of vascular leak syn-
drome. TNF: tumor necrosis factor， 
IFN: interferon， LAK: lymphokine-
activated killer cells， NK: natural kil-
er cells， MOF: multiple organ failure. 
小堀，ほか:インターロイキン 2・腹水
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